GL Ventures and Temasek Lead USD230m Series C for Chinese Biotech Clover Biopharmaceuticals

Source(s): Clover Biopharmaceuticals

GL Ventures and Temasek led a USD230m Series C for Clover Biopharmaceuticals, a China-based clinical-stage biotechnology company and vaccine developer, with participation from Oceanpine Capital and OrbiMed, and follow-on from Delos Capital. Read more